Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

North American Erbitux Sales Up 17 Percent In First Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

Positive clinical trial data, increased promotional efforts with partner Bristol-Myers Squibb drive gains, ImClone reports.
Advertisement

Related Content

FLEX Shows Erbitux’s Strength With Survival Benefit In NSCLC
FLEX Shows Erbitux’s Strength With Survival Benefit In NSCLC
Lilly’s Prasugrel No Match For Clots Compared To Plavix, Bristol Says
Lilly’s Prasugrel No Match For Clots Compared To Plavix, Bristol Says
ImClone Metastatic Breast Cancer Candidate Moves Into Phase III In Third Quarter
ImClone, Sanofi-Aventis Settle Erbitux Patent Dispute

Topics

Advertisement
UsernamePublicRestriction

Register

PS067655

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel